ArticleFrontiers in immunology2025
Distinct metabolomic signatures in allergic rhinitis with concurrent chronic spontaneous urticaria: an untargeted metabolomics analysis reveals novel biomarkers and pathway alterations.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolomics discover distinct metabolite profiles in children with different airway allergic diseases.Frontiers in immunology · 2026Article
- Artemisia pollen-induced allergic rhinitis in mice: multi-omics dissection of local and systemic molecular alterations.Frontiers in allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although allergic rhinitis (AR) and chronic spontaneous urticaria (CSU) share overlapping immunological pathways, their distinct clinical manifestations imply the involvement of unique underlying mechanisms. This study aimed to investigate the metabolomic differences between patients with AR alone and those with concurrent AR and CSU (AR_CSU, defined as patients simultaneously presenting with both conditions). Methods: An untargeted metabolomic analysis was performed on serum samples from 53 AR patients and 14 AR_CSU patients using ultra-performance liquid chromatography coupled with high-resolution mass spectrometry (LC-MS/MS). Multivariate statistical analyses, including partial least squares-discriminant analysis (PLS-DA) and orthogonal partial least squares-discriminant analysis (OPLS-DA), were employed to identify differential metabolites and metabolic pathways. Results: A total of 209 significantly different metabolites were identified between the AR and AR_CSU groups (p < 0.05). Distinct metabolic patterns were observed through PLS-DA and OPLS-DA analyses, with no overlap between the two groups. Twenty metabolites exhibited high diagnostic potential (AUC > 0.75), among which Fasciculic acid C and Biotin-XX-Hydrazide showed particularly strong discriminatory power (AUC ≈ 0.8). Pathway analysis highlighted significant alterations in linoleic acid, fatty acid, and arachidonic acid metabolism. Notably, fatty acid elongation pathways were upregulated in AR_CSU patients, whereas primary bile acid biosynthesis and Fc gamma R-mediated phagocytosis were downregulated. Conclusions: This study represents the first comprehensive metabolomic comparison between AR and AR_CSU, identifying distinct metabolic signatures and potential biomarkers. These findings advance our understanding of the pathophysiological differences between these conditions and could inform the development of targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.